title: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of cisplatin plus gemcitabine in persistent or recurrent platinum-resistant ovarian and primary peritoneal cancer.
  
  
  METHODS
  Eligible, consenting subjects with measurable disease and one prior platinum-based regimen, but no prior gemcitabine, were to receive intravenous cisplatin followed by gemcitabine on days 1 and 8 every 28 days.
  
  
  RESULTS
  Between December 2000 and March 2003, 59 patients were enrolled from 24 institutions; two were ineligible. During the first stage of accrual, 27 subjects received cisplatin 30 mg/m2 and gemcitabine 750 mg/m2. In the second stage, gemcitabine was reduced to 600 mg/m2 because of hematologic toxicity at the higher dose. There were 4 complete and 5 partial responses for an overall response rate of 16% (9/57). Thirty-one women (54%) had stable disease. Median time to progression was 5.4 months. Overall survival was 14.9+ months. Grade 4 toxicities were hematologic, except one cutaneous reaction.
  
  
  CONCLUSIONS
  Cisplatin plus gemcitabine, in the doses and schedule employed, has modest activity in this patient population.
authors.affiliation: UMC Department of Ob/Gyn, Division of Gynecologic Oncology, University of California Irvine and University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4505, USA. CABrewer3@ob-gyn.umsmed.edu
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Brewer
authors.forename: John A
authors.initials: JA
authors.lastname: Blessing
authors.forename: Robert A
authors.initials: RA
authors.lastname: Nagourney
authors.forename: Mark
authors.initials: M
authors.lastname: Morgan
authors.forename: Parviz
authors.initials: P
authors.lastname: Hanjani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine